UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Fusion Protein:BCL2L11-BRAF |
Fusion Protein Summary |
Fusion gene summary |
Fusion partner gene information | Fusion gene name: BCL2L11-BRAF | FusionPDB ID: 9342 | FusionGDB2.0 ID: 9342 | Hgene | Tgene | Gene symbol | BCL2L11 | BRAF | Gene ID | 10018 | 673 |
Gene name | BCL2 like 11 | B-Raf proto-oncogene, serine/threonine kinase | |
Synonyms | BAM|BIM|BOD | B-RAF1|B-raf|BRAF1|NS7|RAFB1 | |
Cytomap | 2q13 | 7q34 | |
Type of gene | protein-coding | protein-coding | |
Description | bcl-2-like protein 11BCL2-like 11 (apoptosis facilitator)bcl-2 interacting mediator of cell deathbcl-2 interacting protein Bimbcl-2-related ovarian death agonist | serine/threonine-protein kinase B-raf94 kDa B-raf proteinB-Raf proto-oncogene serine/threonine-protein kinase (p94)B-Raf serine/threonine-proteinmurine sarcoma viral (v-raf) oncogene homolog B1proto-oncogene B-Rafv-raf murine sarcoma viral oncogene | |
Modification date | 20200313 | 20200329 | |
UniProtAcc | O43521 | P15056 | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000308659, ENST00000337565, ENST00000357757, ENST00000393253, ENST00000393256, ENST00000405953, | ENST00000288602, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 7 X 4 X 6=168 | 48 X 58 X 16=44544 |
# samples | 9 | 69 | |
** MAII score | log2(9/168*10)=-0.900464326449086 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(69/44544*10)=-6.0124909441832 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context (manual curation of fusion genes in FusionPDB) | PubMed: BCL2L11 [Title/Abstract] AND BRAF [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | BCL2L11(111881716)-BRAF(140482957), # samples:3 | ||
Anticipated loss of major functional domain due to fusion event. | BCL2L11-BRAF seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. BCL2L11-BRAF seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. BCL2L11-BRAF seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. BCL2L11-BRAF seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | BCL2L11 | GO:0008630 | intrinsic apoptotic signaling pathway in response to DNA damage | 11546872 |
Hgene | BCL2L11 | GO:0031334 | positive regulation of protein complex assembly | 21041309 |
Hgene | BCL2L11 | GO:0034976 | response to endoplasmic reticulum stress | 22761832 |
Hgene | BCL2L11 | GO:2000271 | positive regulation of fibroblast apoptotic process | 11997495 |
Tgene | BRAF | GO:0000186 | activation of MAPKK activity | 29433126 |
Tgene | BRAF | GO:0006468 | protein phosphorylation | 17563371 |
Tgene | BRAF | GO:0010828 | positive regulation of glucose transmembrane transport | 23010278 |
Tgene | BRAF | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 19667065 |
Tgene | BRAF | GO:0043066 | negative regulation of apoptotic process | 19667065 |
Tgene | BRAF | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 22065586 |
Tgene | BRAF | GO:0071277 | cellular response to calcium ion | 18567582 |
Tgene | BRAF | GO:0090150 | establishment of protein localization to membrane | 23010278 |
Fusion gene breakpoints across BCL2L11 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across BRAF (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Fusion Gene Sample Information |
Fusion gene information from FusionGDB2.0. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | THCA | TCGA-ET-A2MX-01A | BCL2L11 | chr2 | 111881446 | + | BRAF | chr7 | 140482957 | - |
ChimerDB4 | THCA | TCGA-ET-A2MX-01A | BCL2L11 | chr2 | 111881716 | - | BRAF | chr7 | 140482957 | - |
ChimerDB4 | THCA | TCGA-ET-A2MX-01A | BCL2L11 | chr2 | 111881716 | + | BRAF | chr7 | 140482957 | - |
Top |
Fusion ORF Analysis |
Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000337565 | BCL2L11 | chr2 | 111881716 | + | ENST00000288602 | BRAF | chr7 | 140482957 | - | 1744 | 502 | 126 | 1625 | 499 |
ENST00000357757 | BCL2L11 | chr2 | 111881716 | + | ENST00000288602 | BRAF | chr7 | 140482957 | - | 1924 | 682 | 126 | 1805 | 559 |
ENST00000308659 | BCL2L11 | chr2 | 111881716 | + | ENST00000288602 | BRAF | chr7 | 140482957 | - | 1744 | 502 | 126 | 1625 | 499 |
ENST00000393256 | BCL2L11 | chr2 | 111881716 | + | ENST00000288602 | BRAF | chr7 | 140482957 | - | 1909 | 667 | 111 | 1790 | 559 |
ENST00000405953 | BCL2L11 | chr2 | 111881716 | + | ENST00000288602 | BRAF | chr7 | 140482957 | - | 1456 | 214 | 0 | 1337 | 445 |
ENST00000337565 | BCL2L11 | chr2 | 111881446 | + | ENST00000288602 | BRAF | chr7 | 140482957 | - | 1654 | 412 | 126 | 1535 | 469 |
ENST00000393253 | BCL2L11 | chr2 | 111881446 | + | ENST00000288602 | BRAF | chr7 | 140482957 | - | 1654 | 412 | 126 | 1535 | 469 |
ENST00000357757 | BCL2L11 | chr2 | 111881446 | + | ENST00000288602 | BRAF | chr7 | 140482957 | - | 1787 | 545 | 340 | 1668 | 442 |
ENST00000308659 | BCL2L11 | chr2 | 111881446 | + | ENST00000288602 | BRAF | chr7 | 140482957 | - | 1654 | 412 | 126 | 1535 | 469 |
ENST00000393256 | BCL2L11 | chr2 | 111881446 | + | ENST00000288602 | BRAF | chr7 | 140482957 | - | 1772 | 530 | 325 | 1653 | 442 |
ENST00000405953 | BCL2L11 | chr2 | 111881446 | + | ENST00000288602 | BRAF | chr7 | 140482957 | - | 1366 | 124 | 0 | 1247 | 415 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000337565 | ENST00000288602 | BCL2L11 | chr2 | 111881716 | + | BRAF | chr7 | 140482957 | - | 0.013307793 | 0.98669213 |
ENST00000357757 | ENST00000288602 | BCL2L11 | chr2 | 111881716 | + | BRAF | chr7 | 140482957 | - | 0.014716662 | 0.9852834 |
ENST00000308659 | ENST00000288602 | BCL2L11 | chr2 | 111881716 | + | BRAF | chr7 | 140482957 | - | 0.013307793 | 0.98669213 |
ENST00000393256 | ENST00000288602 | BCL2L11 | chr2 | 111881716 | + | BRAF | chr7 | 140482957 | - | 0.014069975 | 0.98593 |
ENST00000405953 | ENST00000288602 | BCL2L11 | chr2 | 111881716 | + | BRAF | chr7 | 140482957 | - | 0.007845804 | 0.9921542 |
ENST00000337565 | ENST00000288602 | BCL2L11 | chr2 | 111881446 | + | BRAF | chr7 | 140482957 | - | 0.006178714 | 0.99382126 |
ENST00000393253 | ENST00000288602 | BCL2L11 | chr2 | 111881446 | + | BRAF | chr7 | 140482957 | - | 0.006178714 | 0.99382126 |
ENST00000357757 | ENST00000288602 | BCL2L11 | chr2 | 111881446 | + | BRAF | chr7 | 140482957 | - | 0.003236262 | 0.9967637 |
ENST00000308659 | ENST00000288602 | BCL2L11 | chr2 | 111881446 | + | BRAF | chr7 | 140482957 | - | 0.006178714 | 0.99382126 |
ENST00000393256 | ENST00000288602 | BCL2L11 | chr2 | 111881446 | + | BRAF | chr7 | 140482957 | - | 0.00308201 | 0.99691796 |
ENST00000405953 | ENST00000288602 | BCL2L11 | chr2 | 111881446 | + | BRAF | chr7 | 140482957 | - | 0.002835531 | 0.9971644 |
Top |
Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >9342_9342_1_BCL2L11-BRAF_BCL2L11_chr2_111881446_ENST00000308659_BRAF_chr7_140482957_ENST00000288602_length(amino acids)=469AA_BP=95 MQPPCEPCHTAIASSRYSVRCVPAATASAPFLGPCSPKCLTLTLGLRNARKKDQMAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSL QTEPQGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWH GDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYL HAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYS NINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYA -------------------------------------------------------------- >9342_9342_2_BCL2L11-BRAF_BCL2L11_chr2_111881446_ENST00000337565_BRAF_chr7_140482957_ENST00000288602_length(amino acids)=469AA_BP=95 MQPPCEPCHTAIASSRYSVRCVPAATASAPFLGPCSPKCLTLTLGLRNARKKDQMAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSL QTEPQGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWH GDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYL HAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYS NINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYA -------------------------------------------------------------- >9342_9342_3_BCL2L11-BRAF_BCL2L11_chr2_111881446_ENST00000357757_BRAF_chr7_140482957_ENST00000288602_length(amino acids)=442AA_BP=68 MAPPASPGPFATRSPLFIFMRRSSLLSRSSSGYFSFDTDRSPAPMSCDKSTQTPSPPCQAFNHYLSAMGSTTGLSATPPASLPGSLTNVK ALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGV LRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGD FGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSN -------------------------------------------------------------- >9342_9342_4_BCL2L11-BRAF_BCL2L11_chr2_111881446_ENST00000393253_BRAF_chr7_140482957_ENST00000288602_length(amino acids)=469AA_BP=95 MQPPCEPCHTAIASSRYSVRCVPAATASAPFLGPCSPKCLTLTLGLRNARKKDQMAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSL QTEPQGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWH GDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYL HAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYS NINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYA -------------------------------------------------------------- >9342_9342_5_BCL2L11-BRAF_BCL2L11_chr2_111881446_ENST00000393256_BRAF_chr7_140482957_ENST00000288602_length(amino acids)=442AA_BP=68 MAPPASPGPFATRSPLFIFMRRSSLLSRSSSGYFSFDTDRSPAPMSCDKSTQTPSPPCQAFNHYLSAMGSTTGLSATPPASLPGSLTNVK ALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGV LRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGD FGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSN -------------------------------------------------------------- >9342_9342_6_BCL2L11-BRAF_BCL2L11_chr2_111881446_ENST00000405953_BRAF_chr7_140482957_ENST00000288602_length(amino acids)=415AA_BP=41 MAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSLQTEPQGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTL GRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQW CEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMA PEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQIL -------------------------------------------------------------- >9342_9342_7_BCL2L11-BRAF_BCL2L11_chr2_111881716_ENST00000308659_BRAF_chr7_140482957_ENST00000288602_length(amino acids)=499AA_BP=125 MQPPCEPCHTAIASSRYSVRCVPAATASAPFLGPCSPKCLTLTLGLRNARKKDQMAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSL QTEPQDRSPAPMSCDKSTQTPSPPCQAFNHYLSAMGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSS DDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSL YHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRM QDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELL -------------------------------------------------------------- >9342_9342_8_BCL2L11-BRAF_BCL2L11_chr2_111881716_ENST00000337565_BRAF_chr7_140482957_ENST00000288602_length(amino acids)=499AA_BP=125 MQPPCEPCHTAIASSRYSVRCVPAATASAPFLGPCSPKCLTLTLGLRNARKKDQMAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSL QTEPQDRSPAPMSCDKSTQTPSPPCQAFNHYLSAMGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSS DDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSL YHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRM QDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELL -------------------------------------------------------------- >9342_9342_9_BCL2L11-BRAF_BCL2L11_chr2_111881716_ENST00000357757_BRAF_chr7_140482957_ENST00000288602_length(amino acids)=559AA_BP=185 MQPPCEPCHTAIASSRYSVRCVPAATASAPFLGPCSPKCLTLTLGLRNARKKDQMAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSL QTEPQGNPEGNHGGEGDSCPHGSPQGPLAPPASPGPFATRSPLFIFMRRSSLLSRSSSGYFSFDTDRSPAPMSCDKSTQTPSPPCQAFNH YLSAMGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWH GDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYL HAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYS NINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYA -------------------------------------------------------------- >9342_9342_10_BCL2L11-BRAF_BCL2L11_chr2_111881716_ENST00000393256_BRAF_chr7_140482957_ENST00000288602_length(amino acids)=559AA_BP=185 MQPPCEPCHTAIASSRYSVRCVPAATASAPFLGPCSPKCLTLTLGLRNARKKDQMAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSL QTEPQGNPEGNHGGEGDSCPHGSPQGPLAPPASPGPFATRSPLFIFMRRSSLLSRSSSGYFSFDTDRSPAPMSCDKSTQTPSPPCQAFNH YLSAMGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWH GDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYL HAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYS NINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYA -------------------------------------------------------------- >9342_9342_11_BCL2L11-BRAF_BCL2L11_chr2_111881716_ENST00000405953_BRAF_chr7_140482957_ENST00000288602_length(amino acids)=445AA_BP=71 MAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSLQTEPQDRSPAPMSCDKSTQTPSPPCQAFNHYLSAMGSTTGLSATPPASLPGSLT NVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNE VGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVK IGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKV -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:111881716/chr7:140482957) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
BCL2L11 | BRAF |
FUNCTION: Induces apoptosis and anoikis. Isoform BimL is more potent than isoform BimEL. Isoform Bim-alpha1, isoform Bim-alpha2 and isoform Bim-alpha3 induce apoptosis, although less potent than isoform BimEL, isoform BimL and isoform BimS. Isoform Bim-gamma induces apoptosis. Isoform Bim-alpha3 induces apoptosis possibly through a caspase-mediated pathway. Isoform BimAC and isoform BimABC lack the ability to induce apoptosis. {ECO:0000269|PubMed:11997495, ECO:0000269|PubMed:15486195, ECO:0000269|PubMed:9430630}. | FUNCTION: Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000305}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Tgene | BRAF | chr2:111881446 | chr7:140482957 | ENST00000288602 | 8 | 18 | 428_432 | 392.3333333333333 | 767.0 | Compositional bias | Note=Poly-Ser | |
Tgene | BRAF | chr2:111881716 | chr7:140482957 | ENST00000288602 | 8 | 18 | 428_432 | 392.3333333333333 | 767.0 | Compositional bias | Note=Poly-Ser | |
Tgene | BRAF | chr2:111881446 | chr7:140482957 | ENST00000288602 | 8 | 18 | 457_717 | 392.3333333333333 | 767.0 | Domain | Protein kinase | |
Tgene | BRAF | chr2:111881716 | chr7:140482957 | ENST00000288602 | 8 | 18 | 457_717 | 392.3333333333333 | 767.0 | Domain | Protein kinase | |
Tgene | BRAF | chr2:111881446 | chr7:140482957 | ENST00000288602 | 8 | 18 | 463_471 | 392.3333333333333 | 767.0 | Nucleotide binding | ATP | |
Tgene | BRAF | chr2:111881716 | chr7:140482957 | ENST00000288602 | 8 | 18 | 463_471 | 392.3333333333333 | 767.0 | Nucleotide binding | ATP |
- Not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | BCL2L11 | chr2:111881446 | chr7:140482957 | ENST00000308659 | + | 2 | 5 | 148_162 | 41.333333333333336 | 139.0 | Motif | Note=BH3 |
Hgene | BCL2L11 | chr2:111881446 | chr7:140482957 | ENST00000337565 | + | 2 | 4 | 148_162 | 41.333333333333336 | 113.0 | Motif | Note=BH3 |
Hgene | BCL2L11 | chr2:111881446 | chr7:140482957 | ENST00000357757 | + | 1 | 4 | 148_162 | 0 | 173.0 | Motif | Note=BH3 |
Hgene | BCL2L11 | chr2:111881446 | chr7:140482957 | ENST00000393253 | + | 2 | 4 | 148_162 | 41.333333333333336 | 86.0 | Motif | Note=BH3 |
Hgene | BCL2L11 | chr2:111881446 | chr7:140482957 | ENST00000393256 | + | 1 | 4 | 148_162 | 0 | 199.0 | Motif | Note=BH3 |
Hgene | BCL2L11 | chr2:111881446 | chr7:140482957 | ENST00000405953 | + | 1 | 3 | 148_162 | 41.333333333333336 | 113.0 | Motif | Note=BH3 |
Hgene | BCL2L11 | chr2:111881716 | chr7:140482957 | ENST00000308659 | + | 3 | 5 | 148_162 | 71.33333333333333 | 139.0 | Motif | Note=BH3 |
Hgene | BCL2L11 | chr2:111881716 | chr7:140482957 | ENST00000337565 | + | 3 | 4 | 148_162 | 71.33333333333333 | 113.0 | Motif | Note=BH3 |
Hgene | BCL2L11 | chr2:111881716 | chr7:140482957 | ENST00000357757 | + | 2 | 4 | 148_162 | 131.33333333333334 | 173.0 | Motif | Note=BH3 |
Hgene | BCL2L11 | chr2:111881716 | chr7:140482957 | ENST00000393253 | + | 1 | 4 | 148_162 | 0 | 86.0 | Motif | Note=BH3 |
Hgene | BCL2L11 | chr2:111881716 | chr7:140482957 | ENST00000393256 | + | 2 | 4 | 148_162 | 131.33333333333334 | 199.0 | Motif | Note=BH3 |
Hgene | BCL2L11 | chr2:111881716 | chr7:140482957 | ENST00000405953 | + | 2 | 3 | 148_162 | 71.33333333333333 | 113.0 | Motif | Note=BH3 |
Tgene | BRAF | chr2:111881446 | chr7:140482957 | ENST00000288602 | 8 | 18 | 122_129 | 392.3333333333333 | 767.0 | Compositional bias | Note=Poly-Ser | |
Tgene | BRAF | chr2:111881446 | chr7:140482957 | ENST00000288602 | 8 | 18 | 6_11 | 392.3333333333333 | 767.0 | Compositional bias | Note=Poly-Gly | |
Tgene | BRAF | chr2:111881716 | chr7:140482957 | ENST00000288602 | 8 | 18 | 122_129 | 392.3333333333333 | 767.0 | Compositional bias | Note=Poly-Ser | |
Tgene | BRAF | chr2:111881716 | chr7:140482957 | ENST00000288602 | 8 | 18 | 6_11 | 392.3333333333333 | 767.0 | Compositional bias | Note=Poly-Gly | |
Tgene | BRAF | chr2:111881446 | chr7:140482957 | ENST00000288602 | 8 | 18 | 155_227 | 392.3333333333333 | 767.0 | Domain | RBD | |
Tgene | BRAF | chr2:111881716 | chr7:140482957 | ENST00000288602 | 8 | 18 | 155_227 | 392.3333333333333 | 767.0 | Domain | RBD | |
Tgene | BRAF | chr2:111881446 | chr7:140482957 | ENST00000288602 | 8 | 18 | 234_280 | 392.3333333333333 | 767.0 | Zinc finger | Phorbol-ester/DAG-type | |
Tgene | BRAF | chr2:111881716 | chr7:140482957 | ENST00000288602 | 8 | 18 | 234_280 | 392.3333333333333 | 767.0 | Zinc finger | Phorbol-ester/DAG-type |
Top |
Fusion Protein-Protein Interaction |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160) |
Gene | PPI interactors |
BRAF | YWHAB, YWHAG, YWHAQ, YWHAZ, SFN, HRAS, AKT1, MAPK3, RAP1GAP, RAF1, MRAS, RAP1A, PAK2, TERF1, CCDC88A, NEDD4L, Nedd4, MAP2K1, RNF149, KSR1, BRAP, PRKCE, RPS6KB2, HSP90AA1, BRAF, YWHAE, HSPA5, MAP2K2, HSPA1A, HSPA8, YWHAH, HSPA9, ARAF, CDC37, HSP90AB1, PHKB, LIMK1, IQGAP1, MAPK1, BAD, LIPF, MUS81, Vps4b, FBXW7, FGFR2, BRCA2, VHL, FNTA, HDAC2, PIK3CA, EGFR, PTEN, FNIP1, FNIP2, RAB3GAP1, KRAS, KIAA0141, FKBPL, ARMCX3, KCNC4, RPTOR, CYLD, NRAS, HSPA4, DNAJB6, PDCD11, PIP5K1A, DNAJC15, VANGL1, DNAJC11, FKBP5, HSPA4L, HSP90B1, GNAI2, DNAJC13, GNAS, PPP2CB, HSD11B2, DNAJB11, PLD2, RAP1B, WDR6, CPNE3, MYOF, COPA, UBLCP1, PPP1CA, RAD50, PIP4K2C, PHB, VIM, PGAM1, DNAJA1, MAP2K7, SPRY2, ALDOA, AP2B1, ATP5A1, SSB, IGF1R, JUP, PPP6C, PARP1, HSPB1, NME2, PRDX2, CCT7, RAB1A, FARSA, FASN, EPRS, TRAF2, REST, KIAA1429, NANOG, ITCH, SMURF2, WWP1, WWP2, PPP2CA, PPP2R2A, AURKA, LATS2, MAP2K3, MAP2K6, RASSF1, STK11, TERT, PEBP1, CRBN, FAR1, PSMC4, UBA52, UBB, UBC, RPS27A, HSPA6, HSP90AB3P, DSP, ATAD3A, ATAD3B, P4HB, SDF2L1, SLC25A22, SPTBN4, TMEM33, CTSB, NCL, HPX, TXNDC12, SLC25A11, NDUFA4, CTSV, FBP1, HSD17B3, ZNF189, ZNF510, KIF14, SRC, TRAP1, JTB, S100P, USP28, |
Protein-protein interactors based on sequence similarity (STRING) |
Gene | STRING network |
BCL2L11 | |
BRAF |
- Retained interactions in fusion protein (protein functional feature from UniProt). |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost interactions due to fusion (protein functional feature from UniProt). |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to BCL2L11-BRAF |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to BCL2L11-BRAF |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | BRAF | C0025202 | melanoma | 24 | CGI;CTD_human;UNIPROT |
Tgene | BRAF | C1275081 | Cardio-facio-cutaneous syndrome | 14 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Tgene | BRAF | C0009402 | Colorectal Carcinoma | 8 | CTD_human;UNIPROT |
Tgene | BRAF | C0028326 | Noonan Syndrome | 8 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET |
Tgene | BRAF | C0238463 | Papillary thyroid carcinoma | 8 | CTD_human;ORPHANET |
Tgene | BRAF | C0040136 | Thyroid Neoplasm | 6 | CGI;CTD_human |
Tgene | BRAF | C0151468 | Thyroid Gland Follicular Adenoma | 6 | CTD_human |
Tgene | BRAF | C0175704 | LEOPARD Syndrome | 6 | CLINGEN;GENOMICS_ENGLAND |
Tgene | BRAF | C0549473 | Thyroid carcinoma | 6 | CGI;CTD_human |
Tgene | BRAF | C3150970 | NOONAN SYNDROME 7 | 5 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | BRAF | C0009404 | Colorectal Neoplasms | 4 | CTD_human |
Tgene | BRAF | C3150971 | LEOPARD SYNDROME 3 | 4 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | BRAF | C1519086 | Pilomyxoid astrocytoma | 3 | ORPHANET |
Tgene | BRAF | C0004565 | Melanoma, B16 | 2 | CTD_human |
Tgene | BRAF | C0009075 | Melanoma, Cloudman S91 | 2 | CTD_human |
Tgene | BRAF | C0018598 | Melanoma, Harding-Passey | 2 | CTD_human |
Tgene | BRAF | C0023443 | Hairy Cell Leukemia | 2 | CGI;ORPHANET |
Tgene | BRAF | C0025205 | Melanoma, Experimental | 2 | CTD_human |
Tgene | BRAF | C0033578 | Prostatic Neoplasms | 2 | CTD_human |
Tgene | BRAF | C0152013 | Adenocarcinoma of lung (disorder) | 2 | CGI;CTD_human |
Tgene | BRAF | C0376358 | Malignant neoplasm of prostate | 2 | CTD_human |
Tgene | BRAF | C0587248 | Costello syndrome (disorder) | 2 | CLINGEN;CTD_human |
Tgene | BRAF | C3501843 | Nonmedullary Thyroid Carcinoma | 2 | CTD_human |
Tgene | BRAF | C3501844 | Familial Nonmedullary Thyroid Cancer | 2 | CTD_human |
Tgene | BRAF | C0002448 | Ameloblastoma | 1 | CTD_human |
Tgene | BRAF | C0004114 | Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0010276 | Craniopharyngioma | 1 | CTD_human;ORPHANET |
Tgene | BRAF | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
Tgene | BRAF | C0017638 | Glioma | 1 | CGI;CTD_human |
Tgene | BRAF | C0019621 | Histiocytosis, Langerhans-Cell | 1 | CGI;ORPHANET |
Tgene | BRAF | C0022665 | Kidney Neoplasm | 1 | CTD_human |
Tgene | BRAF | C0023903 | Liver neoplasms | 1 | CTD_human |
Tgene | BRAF | C0024232 | Lymphatic Metastasis | 1 | CTD_human |
Tgene | BRAF | C0024694 | Mandibular Neoplasms | 1 | CTD_human |
Tgene | BRAF | C0027659 | Neoplasms, Experimental | 1 | CTD_human |
Tgene | BRAF | C0027962 | Melanocytic nevus | 1 | GENOMICS_ENGLAND |
Tgene | BRAF | C0036920 | Sezary Syndrome | 1 | CTD_human |
Tgene | BRAF | C0041409 | Turner Syndrome, Male | 1 | CTD_human |
Tgene | BRAF | C0079773 | Lymphoma, T-Cell, Cutaneous | 1 | CTD_human |
Tgene | BRAF | C0205768 | Subependymal Giant Cell Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0206686 | Adrenocortical carcinoma | 1 | CTD_human |
Tgene | BRAF | C0206754 | Neuroendocrine Tumors | 1 | CTD_human |
Tgene | BRAF | C0259783 | mixed gliomas | 1 | CTD_human |
Tgene | BRAF | C0278875 | Adult Craniopharyngioma | 1 | CTD_human |
Tgene | BRAF | C0280783 | Juvenile Pilocytic Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0280785 | Diffuse Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0334579 | Anaplastic astrocytoma | 1 | CGI;CTD_human |
Tgene | BRAF | C0334580 | Protoplasmic astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0334581 | Gemistocytic astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0334582 | Fibrillary Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0334583 | Pilocytic Astrocytoma | 1 | CGI;CTD_human |
Tgene | BRAF | C0338070 | Childhood Cerebral Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0345904 | Malignant neoplasm of liver | 1 | CTD_human |
Tgene | BRAF | C0376407 | Granulomatous Slack Skin | 1 | CTD_human |
Tgene | BRAF | C0406803 | Syringocystadenoma Papilliferum | 1 | GENOMICS_ENGLAND |
Tgene | BRAF | C0431128 | Papillary craniopharyngioma | 1 | CTD_human |
Tgene | BRAF | C0431129 | Adamantinous Craniopharyngioma | 1 | CTD_human |
Tgene | BRAF | C0547065 | Mixed oligoastrocytoma | 1 | CTD_human |
Tgene | BRAF | C0555198 | Malignant Glioma | 1 | CTD_human |
Tgene | BRAF | C0596263 | Carcinogenesis | 1 | CTD_human |
Tgene | BRAF | C0684249 | Carcinoma of lung | 1 | CGI;UNIPROT |
Tgene | BRAF | C0740457 | Malignant neoplasm of kidney | 1 | CTD_human |
Tgene | BRAF | C0750935 | Cerebral Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0750936 | Intracranial Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0751061 | Craniopharyngioma, Child | 1 | CTD_human |
Tgene | BRAF | C0920269 | Microsatellite Instability | 1 | CTD_human |
Tgene | BRAF | C1527404 | Female Pseudo-Turner Syndrome | 1 | CTD_human |
Tgene | BRAF | C1704230 | Grade I Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C1721098 | Replication Error Phenotype | 1 | CTD_human |
Tgene | BRAF | C2239176 | Liver carcinoma | 1 | CTD_human |
Tgene | BRAF | C4551484 | Leopard Syndrome 1 | 1 | GENOMICS_ENGLAND |
Tgene | BRAF | C4551602 | Noonan Syndrome 1 | 1 | CTD_human |
Tgene | BRAF | C4721532 | Lymphoma, Non-Hodgkin, Familial | 1 | UNIPROT |
Tgene | BRAF | C4733333 | familial non-medullary thyroid cancer | 1 | GENOMICS_ENGLAND |